MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Oragenics Cash and Cash Equivalents 2011-2026 | OGEN
Annual Cash and Cash Equivalents Oragenics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.4 M | 865 K | 3.48 M | 11.4 M | 27.3 M | 17.6 M | 18.3 M | 20.2 M | 6.17 M | 4.08 M | 5.08 M | 10.4 M | 16.3 M | 9.93 M | 172 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 27.3 M | 172 K | 10.4 M |
Quarterly Cash and Cash Equivalents Oragenics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.4 M | 1.97 M | 3.42 M | 865 K | 3.14 M | 1.35 M | 2.07 M | 3.48 M | 5.77 M | 6.47 M | 9.16 M | 11.4 M | 14 M | 17.9 M | 21.4 M | 27.3 M | 29.9 M | 34.6 M | 36.5 M | 17.6 M | 17.6 M | 17.6 M | 17.6 M | 18.3 M | 18.3 M | 18.3 M | 18.3 M | 20.2 M | 20.2 M | 20.2 M | 20.2 M | 6.17 M | 6.17 M | 6.17 M | 6.17 M | 4.08 M | 4.08 M | 4.08 M | 4.08 M | 5.08 M | 5.08 M | 5.08 M | 5.08 M | 10.4 M | 10.4 M | 10.4 M | 10.4 M | 16.3 M | 16.3 M | 16.3 M | 16.3 M | 9.93 M | 9.93 M | 9.93 M | 9.93 M | 172 K | 172 K | 172 K | 172 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 36.5 M | 172 K | 11.4 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | USA |
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
34.8 M | $ 3.83 | 2.56 % | $ 9.21 B |  Australia |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
1.66 B | $ 327.37 | -1.81 % | $ 42.9 B | USA |
 |
Applied Molecular Transport
AMTI
|
61.1 M | - | - | $ 10.1 M | USA |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
98.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Burford Capital Limited
BUR
|
322 M | $ 4.74 | 0.21 % | $ 767 M |  Britain |
 |
Cabaletta Bio
CABA
|
83 M | $ 3.48 | 2.39 % | $ 350 M | USA |
 |
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M | France |
 |
Aligos Therapeutics
ALGS
|
18.3 M | $ 8.22 | 10.78 % | $ 81.3 M | USA |
 |
Allakos
ALLK
|
66.4 M | - | - | $ 28.6 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M |  Israel |
 |
Midatech Pharma plc
MTP
|
8.53 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Therapeutics
APLT
|
49.9 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
56.2 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
53.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
29 K | - | -2.5 % | $ 5.88 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
170 M | $ 21.55 | -0.6 % | $ 1.01 B | USA |
 |
CymaBay Therapeutics
CBAY
|
207 M | - | - | $ 3.45 B | USA |
 |
BioNTech SE
BNTX
|
7.68 B | $ 100.72 | 1.25 % | $ 27.2 B | Germany |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
7.31 M | - | 5.93 % | $ 314 M |  Canada |
 |
Can-Fite BioPharma Ltd.
CANF
|
8.27 M | $ 3.1 | -2.21 % | $ 5.1 M | Israel |
 |
AgeX Therapeutics
AGE
|
3.06 M | - | -10.17 % | $ 12.2 K | USA |
 |
ContraFect Corporation
CFRX
|
8.91 M | - | -5.16 % | $ 5.39 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
185 M | $ 1.42 | -8.71 % | $ 365 M | USA |
 |
Galectin Therapeutics
GALT
|
17.7 M | $ 2.39 | -6.65 % | $ 153 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
121 M | $ 4.18 | -1.3 % | $ 447 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
42.9 M | $ 24.21 | -1.53 % | $ 3.08 B | USA |
 |
AIkido Pharma
AIKI
|
34 M | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
112 M | - | -4.8 % | $ 255 M | USA |
 |
Grifols, S.A.
GRFS
|
980 M | $ 8.58 | -1.27 % | $ 6.83 B |  Spain |
 |
Autolus Therapeutics plc
AUTL
|
104 M | $ 1.52 | 1.68 % | $ 405 M | Britain |
 |
Aptose Biosciences
APTO
|
935 K | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
4.55 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Checkpoint Therapeutics
CKPT
|
6.6 M | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
16.2 M | - | -16.75 % | $ 25.8 M | USA |
 |
AVROBIO
AVRO
|
98 M | - | 1083.1 % | $ 745 M | USA |
 |
Clearside Biomedical
CLSD
|
28.9 M | - | - | $ 25.3 M | USA |
 |
Celldex Therapeutics
CLDX
|
28.9 M | $ 33.67 | -0.61 % | $ 2.24 B | USA |
 |
bluebird bio
BLUE
|
222 M | - | - | $ 546 M | USA |